Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    EUSA
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Fate Therapetuics
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Genentech
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    GenMab
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    InstilBio
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Ipsen
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Janssen
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Kite
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Loxo
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Miltenyi
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023

Pages

Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes